At the same time, we've remained focused on helping the world through the pandemic.
In the third quarter, we delivered strong results.
Revenue totaled $4.1 billion, adjusted earnings per share reached $6.82, and free cash flow was $650 million.
As a result of our strong performance and our improved outlook, we're raising full year guidance for revenue, adjusted earnings per share and free cash flow.
The Base Business for both Diagnostics and Drug Development performed well with 10% and 22% growth, respectively.
Labcorp continues to support the fight against the pandemic in every way possible through both our diagnostic and our drug development capabilities.
Capital expenditures totaled $118 million or 2.9% of revenue compared to $77 million or 2% of revenue last year.
As a result, free cash flow was $650 million in the quarter compared to $709 million last year.
